Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Enzyme Replacement Therapy During Pregnancy in Fabry Patients: Review of Published Cases of Live Births and a New Case of a Severely Affected Female with Fabry Disease and Pre-eclampsia Complicating Pregnancy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Completeness of RET testing in patients with medullary thyroid carcinoma in Denmark 1997-2013: a nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Diagnosis of Hypothyroidism

    Publikation: Bog/antologi/afhandling/rapportBogForskningpeer review

  5. Replication of newly proposed TNM staging system for medullary thyroid carcinoma: a nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Fabry disease (FD) is an X-linked, lysosomal storage disease. Mutations in the gene coding for alpha-galactosidase A lead to globotriaosylceramide (Gb-3) accumulation in lysosomes and in placenta and umbilical cord. Impact of FD and treatment with enzyme replacement (ERT) on foetal development is undisclosed.A 38-year-old primigravida with FD (G85N) is reported. She has 50% reduced alpha-galactosidase A activity and elevated plasma and urine-Gb-3. She was severely affected with ischaemic stroke at age 23, hypertension, albuminuria and moderately reduced renal function. ERT was initiated at age 23 years in 2001 and continued during spontaneous pregnancy at age 38. In third trimester she developed moderate-to-severe pre-eclampsia, successfully managed by methyldopa. Chorion villus sampling revealed a male foetus without the maternal gene mutation. Planned Caesarean section was performed without complications at gestational age week 38 + 6, delivering a healthy boy. Histopathological placental examination showed no sign of Gb-3 accumulation. Literature survey disclosed a total of 12 cases, 8 were treated with ERT during pregnancy and 5 infants inherited the family mutation. All outcomes were successful. In the six cases with available placental histopathological examination, Gb-3 accumulation was only seen on the foetal side if the foetus had the inherited mutation.In conclusion, the present case, describing the first data from a severely affected FD patient receiving ERT during pregnancy complicated by pre-eclampsia, together with all other published cases, has emphasized that ERT is safe during pregnancy and resulting in successful foetal outcome; despite this, ERT is by the health authorities advised against during pregnancy.

TidsskriftJIMD Reports
Sider (fra-til)93-101
StatusUdgivet - 2019

ID: 55073229